CA Patent

CA3165168A1 — Compounds and methods for the targeted degradation of androgen receptor

Assigned to Arvinas Operations Inc · Expires 2021-06-24 · 5y expired

What this patent protects

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

USPTO Abstract

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3165168A1
Jurisdiction
CA
Classification
—
Expires
2021-06-24
Drug substance claim
No
Drug product claim
No
Assignee
Arvinas Operations Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.